Sex Differences in Neurobehavioral Response to THC
2 other identifiers
interventional
40
1 country
1
Brief Summary
This study investigates sex differences in reward processing following acute THC administration in adults with cannabis use disorder (CUD). Using multimodal neuroimaging (MRS and fMRI), the study will assess glutamate levels in the nucleus accumbens and striatal BOLD response to monetary reward anticipation. Participants will complete two counterbalanced dosing sessions (oral THC 40 mg vs. placebo).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Apr 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 5, 2025
CompletedFirst Posted
Study publicly available on registry
November 10, 2025
CompletedStudy Start
First participant enrolled
April 27, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
May 6, 2026
May 1, 2026
1.7 years
November 5, 2025
May 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Nucleus accumbens glutamate
Concentrations of nucleus accumbens glutamate measured via proton magnetic resonance spectroscopy
2 hours post-dose
Striatal reward anticipation
Blood oxygen-level-dependent (BOLD) signaling in the striatum (caudate, putamen, nucleus accumbens) measured using functional magnetic resonance imaging (fMRI) during a monetary reward task
3 hours post-dose
Secondary Outcomes (4)
Drug Effects Questionnaire (DEQ) - Like Drug Effect
0-7 hours
Drug Effects Questionnaire (DEQ) - Want More
0-7 hours
Drug Effects Questionnaire (DEQ) - High
0-7 hours
Nucleus accumbens GABA
2 hours post-dose
Study Arms (2)
Males
OTHERFemales
OTHERInterventions
Eligibility Criteria
You may qualify if:
- Age 21-45
- DSM-5 criteria for CUD
- Cannabis use ≥4 days/week
- THC-positive urine
- BMI 18-30
- Regular menstrual cycle (females)
- Willingness to use non-hormonal birth control (females)
You may not qualify if:
- Lifetime psychotic or bipolar disorder
- Recent drug use other than cannabis
- Current psychotropic medication
- Treatment-seeking for SUD
- Current psychiatric disorder (except mild alcohol, nicotine, or caffeine use disorder)
- Pregnancy/nursing
- MRI contraindications
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Medical University of South Carolinalead
- National Institutes of Health (NIH)collaborator
- National Institute on Drug Abuse (NIDA)collaborator
Study Sites (1)
Medical University of South Carolina
Charleston, South Carolina, 29403, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Erin Martin, Ph.D.
Medical University of South Carolina
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Research Assistant Professor-Faculty
Study Record Dates
First Submitted
November 5, 2025
First Posted
November 10, 2025
Study Start
April 27, 2026
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2027
Last Updated
May 6, 2026
Record last verified: 2026-05